Dupilumab

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis

Trial Timeline

May 15, 2024 → Nov 3, 2027

NCT ID

NCT06293053

About Dupilumab

Dupilumab is a phase 3 stage product being developed by Sanofi for Prurigo Nodularis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06293053. Target conditions include Prurigo Nodularis.

What happened to similar drugs?

1 of 6 similar drugs in Prurigo Nodularis were approved

Approved (1) Terminated (0) Active (5)

✅UpadacitinibAbbVieApproved

🔄Rocatinlimab + PlaceboAmgenPhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

🔄Povorcitinib + PlaceboIncytePhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05906706	Pre-clinical	Completed	—	—	Bullous Pemphigoid
NCT07316114	Pre-clinical	Recruiting	Feb 28, 2026	Nov 22, 2029	Chronic Spontaneous Urticaria
NCT07467564	Pre-clinical	Recruiting	Feb 24, 2026	May 24, 2027	Atopic Dermatitis
NCT07187089	Approved	Withdrawn	Nov 11, 2025	Jan 5, 2028	Severe Atopic Dermatitis (AD)
NCT07112378	Phase 3	Recruiting	Nov 10, 2025	Oct 9, 2028	Eosinophilic Esophagitis (EoE)
NCT07052396	Pre-clinical	Recruiting	Jul 1, 2025	Jul 1, 2029	Chronic Obstructive Pulmonary Disease (COPD)
NCT07276425	Pre-clinical	Recruiting	Jun 1, 2025	Jun 1, 2028	Prurigo Nodularis (PN)
NCT06695897	Pre-clinical	Recruiting	Dec 2, 2024	May 29, 2029	Eosinophilic Esophagitis
NCT06693531	Pre-clinical	Recruiting	Nov 22, 2024	May 22, 2030	Eosinophilic Esophagitis (EoE)
NCT06415175	Pre-clinical	Active	Nov 14, 2024	Nov 23, 2027	Atopic Dermatitis
NCT06556264	Approved	Recruiting	Aug 1, 2024	Dec 1, 2025	Chronic Rhinosinusitis With Nasal Polyps
NCT06352073	Approved	Recruiting	May 16, 2024	Dec 1, 2026	Eosinophilic Esophagitis
NCT06293053	Phase 3	Recruiting	May 15, 2024	Nov 3, 2027	Prurigo Nodularis
NCT05983068	Approved	Active	Feb 22, 2024	Aug 7, 2026	Dermatitis Atopic
NCT06234761	Pre-clinical	Recruiting	Jan 2, 2024	Dec 1, 2028	Pathophysiology
NCT05991323	Pre-clinical	Active	Dec 12, 2023	Sep 22, 2026	Prurigo Nodularis
NCT06192563	Pre-clinical	Recruiting	Nov 30, 2023	Jan 31, 2026	Dermatitis Atopic
NCT06169527	Pre-clinical	Active	Nov 28, 2023	May 10, 2028	Atopic Dermatitis
NCT06393946	Pre-clinical	Active	Oct 20, 2023	Jul 31, 2026	Chronic Rhinosinusitis With Nasal Polyposis
NCT05831176	Phase 2	Active	May 3, 2023	Nov 25, 2026	Eosinophilic Gastritis (EoG)

Competing Products

20 competing products in Prurigo Nodularis

See all competitors

Product	Company	Stage	Hype Score
Vixarelimab + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
Upadacitinib	AbbVie	Approved	50
Pimecrolimus + Hydrocortisone + Pimecrolimus	Novartis	Phase 2	35
Rocatinlimab + Placebo	Amgen	Phase 3	44
Abrocitinib	Pfizer	Phase 2	35
Dupilumab SAR231893 (REGN668)	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Pre-clinical	30
Ruxolitinib Cream 1.5%	Incyte	Phase 1	26
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
INCB054707 + Placebo	Incyte	Phase 2	32
Povorcitinib + Placebo	Incyte	Phase 3	44
Povorcitinib + Placebo	Incyte	Phase 3	44
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
CDX-0159 + Normal saline	Celldex Therapeutics	Phase 1	23
barzolvolimab	Celldex Therapeutics	Phase 2	33
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID	Trevi Therapeutics	Phase 2/3	32
nalbuphine HCl ER	Trevi Therapeutics	Phase 2/3	32
Nalbuphine ER Tablets + Placebo Tablets	Trevi Therapeutics	Phase 2/3	32
serlopitant + Placebo	Vyne Therapeutics	Phase 2	25